Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic saline 7% plus versus hypertonic saline 7% for Pseudomonas aeruginosa in cystic fibrosis
IRCT20201017049055N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hypertonic saline in cystic fibrosis (CF) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Weight, Pseudomonas aeruginosa colony count in sputum culture and 4 more. Started Dec 2020; status: completed.
02
Drugs
hypertonic saline
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on IRCT20201017049055N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201017049055N1.